Inlyta 5mg Tablet

The majority of adverse effects go away as your body becomes used to the medication and doesn't need to be treated. If they continue or you're concerned about them, speak with your doctor. Side effects of Inlyta 5mg are as follws:

• Dizziness

• Nausea and vomiting

• Constipation or diarrhea

• Loss of appetite

• Weight loss

• Headache

• Muscle and joint pain

• Weakness and fatigue

• Dry skin, itching, redness, or hair loss

• Nosebleeds

• Ringing in the ears

• Sore throat

• Voice changes

• Anemia (low red blood cell count)

• Elevated creatinine levels (possible kidney problems)

• Dehydration

• Palmar-plantar erythrodysesthesia (hand-foot syndrome: redness, swelling, pain in palms/soles)

• Severe fatigue with swelling

• Chest pain or pressure (may spread to arms, back, neck, or jaw)

• Shortness of breath or difficulty speaking

• Significant bleeding (such as black stools or coughing up blood)

• ​Inlyta 5mg tablet comes in tablet form and is usually taken with or without food twice a day or as the doctor prescribes.
• For better results, take Axitinib same time every 12 hours.
• You should not cut, chew, or break the tablet; swallow the whole tablet with water.
• If the patient vomits after taking a tablet, do not give another; take the tablet as per the schedule.
• If the patient feels uncomfortable after starting treatment, inform the doctor immediately.

• Axitinib 5mg targets tyrosine kinases on the surface of VEGFR. Through this, it works by interrupting signals required for tumor proliferation through these receptors.
• The main action of axitinib involves angiogenesis inhibition. This is the development of blood vessels responsible for tumor development.
• It does so mainly through VEGFR-1, -2, and -3 that are highly expressed in advanced renal cell carcinoma (RCC)
  
• The inhibition of angiogenesis leads to effective starvation of the tumor.
  

• Take Inlyta with or without food, preferably at the same time each day.
  
• Monitor your blood pressure regularly; report severe headache, vision problems, confusion, nausea, or vomiting.
  
• Thyroid function should be checked before and during treatment, as hypothyroidism may occur.
  
• Watch for signs of bleeding (black stools, blood in urine or cough, stomach pain, and headaches) and inform your doctor immediately.
  
• Stop the medication at least 24 hours before elective surgery to avoid wound‑healing complications.
  
• Dose reduction may be required in patients with moderate liver impairment (starting dose 2 mg twice daily).
  
• Use effective contraception during treatment and for one month after stopping, as the tablet is contraindicated in pregnancy.
  
• Diarrhea is a possible side effect; stay hydrated and seek medical advice if persistent or if blood is present in stools.​
  

• Fox, E., Maris, J. M., Widemann, B. C., Goodspeed, W., Goodwin, A., Kromplewski, M., & Blaney, S. M. (2018).  A phase 1 study of axitinib in pediatric patients with refractory solid tumors: A Children’s Oncology Group study (ADVL1215). Clinical Cancer Research, 24(14), 3534–3541.
  
• Fu, L., Liu, Q., Han, Z., Wu, Y., & Jiang, Y. (2023).  Axitinib for hepatocellular carcinoma: Mechanisms and emerging immunotherapy combination strategies. Frontiers in Immunology, 14, 1163967.
  
• Jeong, I. G., Park, J., Ahn, H. K., Park, S. H., Song, C., Hong, B., & Lee, J. L. (2024). Real-world use of axitinib as a second-line therapy in patients with metastatic renal cell carcinoma: A Korean multicenter phase IV study. Investigational and Clinical Urology, 65(2), 136–144 - https://pubmed.ncbi.nlm.nih.gov/39057291/
  
• Powell, S. F., Choueiri, T. K., Motzer, R. J., Escudier, B., Grunwald, V., Donskov, F., & Rini, B. I. (2023). Final overall survival and biomarker analysis of avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (JAVELIN Renal 101). European Urology, 84(3), 320–329 - https://pubmed.ncbi.nlm.nih.gov/39057291/
  
• Teoh, J. Y. C., Leung, C. H., Chan, C. M., Poon, D. M. C., & Ng, C. F. (2024). Systematic review of axitinib for advanced renal cell carcinoma: Real-world evidence and future directions. Cancers, 16(7), 1605
  
• Voss, M. H., Keegan, M. E., Clark, J. W., Halabi, S., McKay, R. R., Atkins, M. B., & Pal, S. K. (2023). Management of adverse events associated with axitinib plus immune checkpoint inhibitor combinations: A real-world multicenter analysis. Targeted Oncology, 18(3), 319–329 - https://pubmed.ncbi.nlm.nih.gov/32587360/